ABBVIE
🇫🇷France
A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Subjects With Genotype 1 Infection
- First Posted Date
- 2015-11-13
- Last Posted Date
- 2021-07-13
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 703
- Registration Number
- NCT02604017
A Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis
- First Posted Date
- 2015-11-11
- Last Posted Date
- 2018-05-17
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 20
- Registration Number
- NCT02601885
- Locations
- 🇺🇸
Rowe Neurology Institute, Lenexa, Kansas, United States
🇺🇸Compass Research LLC, Orlando, Florida, United States
🇺🇸Parexel International, Baltimore, Maryland, United States
Study Evaluating Duvelisib in Japanese Subjects With Relapsed or Refractory Lymphoma
- First Posted Date
- 2015-11-06
- Last Posted Date
- 2017-02-06
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 7
- Registration Number
- NCT02598570
- Locations
- 🇯🇵
Site Reference ID/Investigator# 141595, Fukuoka, Japan
🇯🇵Site Reference ID/Investigator# 141826, Aichi, Japan
🇯🇵Site Reference ID/Investigator# 141594, Tokyo, Japan
Safety, Tolerability and Pharmacokinetics of BI 655066/ABBV-066 (Risankizumab) in Healthy Asian and Caucasian Male Volunteers
- First Posted Date
- 2015-11-04
- Last Posted Date
- 2017-07-06
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 80
- Registration Number
- NCT02596217
- Locations
- 🇰🇷
Boehringer Ingelheim Investigational Site, Busan, Korea, Republic of
Study Evaluating ABT-414 in Japanese Subjects With Malignant Glioma
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-10-29
- Last Posted Date
- 2020-09-03
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 53
- Registration Number
- NCT02590263
- Locations
- 🇯🇵
University of Tsukuba Hospital /ID# 140433, Tsukuba-shi, Ibaraki, Japan
🇯🇵Osaka University Hospital /ID# 140438, Suita-shi, Osaka, Japan
🇯🇵Iwate Medical University Hospital /ID# 149145, Shiwa-gun, Iwate, Japan
Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Austria (REAL)
Completed
- Conditions
- First Posted Date
- 2015-10-21
- Last Posted Date
- 2019-06-05
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 173
- Registration Number
- NCT02582658
The Effectiveness of ABT-450/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C -An Observational Study in Ireland
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-10-21
- Last Posted Date
- 2019-05-06
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 101
- Registration Number
- NCT02582671
A Study to Evaluate Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Hepatitis C Virus Genotype 1b-Infected Adults
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-10-21
- Last Posted Date
- 2021-07-30
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 166
- Registration Number
- NCT02582632
The Effectiveness of Dual Therapy (Lopinavir/Ritonavir + LamivudinE) in Treatment-Experienced HIV Infected Patients in the Russian Federation
- First Posted Date
- 2015-10-20
- Last Posted Date
- 2019-06-06
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 216
- Registration Number
- NCT02581202
Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Canada
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-10-20
- Last Posted Date
- 2019-03-27
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 565
- Registration Number
- NCT02581189
© Copyright 2024. All Rights Reserved by MedPath